

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/674,975
				Filing Date	November 7, 2000
				First Named Inventor	Agus
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	MSKP039
Sheet	1	of	2		

[illegible][illegible]

1.

7/17/03

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+


Please type a plus sign (+) inside this box →

+

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/674,975
				Filing Date	November 7, 2000
				First Named Inventor	Aqus
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	MSKP039



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM		NAFTZGER, et al, Immune Response to a Differentiation Antigen Induced by Altered Antigen; A Study of Tumor Rejection and Autoimmunity; Proc. Natl. Acad. Sci. USA, December 1996, pp. 14809-14814; Vol. 93; Medical Sciences. ✓	
		Database BIOSIS, AN 1997:22684, HOOJBERG et al. Lysis of Syngeneic Tumor B Cells by Autoreactive Cytotoxic T Lymphocytes Specific for a CD19 Antigen-Derived Synthetic Peptide. J. Immunoth. 1996, Vol. 19, No. 5, pages 346-356, see especially the Abstract. ✓	
		HARLOW and Lane, 1988, Antibodies a Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, p. 72	
		ROWELL, et al, Lysosome-Associated Membrane Protein-1-Mediated Targeting of the HIV-1 Envelope Protein to an Endosomal/Lysosomal Compartment Enhances Its Presentation to MHC Class II-Restricted T Cells. The Journal of Immunology, 1995, pp1818-1828, 155. ✓	
		VIJAYASARADHI, et al, Intracellular Sorting and Targeting of Melanosomal Membrane Proteins: Identification of Signals for Sorting of the Human Brown Locus Protein, GP75. Journal of Cell Biology, August 1995, pp. 807-820, Volume 130, The Rockefeller University Press. ✓	
		PARDOLL, et al, Exposing the Immunology of Naked DNA Vaccines. Immunity, August, 1995, pp. 165-69, Vol. 3, Cell Press. ✓	
		NANDA, et al, Induction of Anti-Self-Immunity To Cure Cancer. Cell, Vol. 82, pp. 13-17, Cell Press. ✓	
		KRISHNAN, et al, Paving the Way Towards DNA Vaccines. Nature Medicine, June 1995, pp.521-22, Volume 1, ✓	
		TIFFET, et al, The Folding and Cell Surface Expression of CD4 Requires Glycosylation. Journal of Biological Chemistry, February 15, 1992, pp. 3266-3273, Vol. 267, No. 5. ✓	
		ULMER, et al, Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein. Science, 19 March 1993, pp. 1745-49, Vol. 259. ✓	

Examiner Signature	7/17/03	Date Considered	7/17/03
--------------------	---------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.